Certara Products - Simcyp Archives | Page 7 of 23

White Paper

Overcome Research Hurdles: Expert Guidance for Complex Generic Drug Development

Do expensive bioequivalence studies stall your generic drug approval? Learn how you can streamline complex…

CertaraApril 15, 2021

On-Demand Webinar

Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure

The European Medicines Agency (EMA) recently approved dulaglutide (Trulicity®) at higher doses (3 mg and…

CertaraApril 1, 2021

Publication

Physiologically- based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1%

CertaraMarch 16, 2021

On-Demand Webinar

IQ WG Evaluation of PBPK Models for Organ-Impaired Populations

• The predictive performance of physiologically based pharmacokinetic(s) (PBPK) models for PK in renal impairment…

CertaraMarch 10, 2021

White Paper

Advancing Pediatric Drug Development Using Simcyp PBPK

CertaraMarch 4, 2021

Brochure

Simcyp™ PBPK Simulator

Streamlines drug development by using PBPK modeling to predict drug behavior in virtual populations, optimize…

CertaraJanuary 22, 2021

Publication

Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters

CertaraNovember 13, 2020

Press Coverage

How PBPK Modeling Can Replace Drug-Drug Interaction Studies

Patients often take more than one drug at a time, especially elderly patients and those…

CertaraNovember 12, 2020

Case Study

Galderma Achieves FDA Approval of AKLIEF® (trifarotene)

In October 2019, Galderma announced that the U.S. FDA approved AKLIEF® (trifarotene) Cream, 0.005% for the…

CertaraNovember 9, 2020

Publication

Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics

CertaraOctober 30, 2020

Certara Products – Simcyp

Overcome Research Hurdles: Expert Guidance for Complex Generic Drug Development

Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure

Physiologically- based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1%

IQ WG Evaluation of PBPK Models for Organ-Impaired Populations

Advancing Pediatric Drug Development Using Simcyp PBPK

Simcyp™ PBPK Simulator

Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters

How PBPK Modeling Can Replace Drug-Drug Interaction Studies

Galderma Achieves FDA Approval of AKLIEF® (trifarotene)

Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics

Newsletter sign up

Quick links

Solutions

Contact